From Injections to Pills: A Blueprint for Oral GLP-1 Drugs
- This J. Med. Chem. perspective synthesizes lessons from four clinical-stage oral, nonpeptidic GLP-1 receptor agonists—danuglipron, lotiglipron, DA-302168S, and orforglipron—to outline a design blueprint for next-generation candidates.
- It frames a broader modality shift in metabolic disease therapeutics: from injectable peptide GLP-1RAs toward oral small molecules that could improve dosing convenience and patient acceptance.
- Orforglipron is highlighted as the first oral small-molecule GLP-1RA to reach approval, marking a proof-of-concept milestone for the class.
- The authors distill recurring structure-activity relationship tradeoffs among these first-generation candidates—balancing receptor potency, tolerability, and oral bioavailability—that shaped each program's clinical trajectory.
- Based on these comparisons, the review proposes design principles intended to guide future medicinal chemistry efforts toward improved oral GLP-1RAs.
GLP-1R's orthosteric pocket is deep and peptide-shaped — basically undruggable at drug-like MW/logP, so all four of these (danuglipron, lotiglipron, DA-302168S, orforglipron) work through allosteric or biased engagement rather than mimicking the peptide directly. That's the clever workaround, but it means potency, selectivity, and clean signaling bias have to be re-optimized empirically each time instead of inherited from orthosteric geometry. GI tolerability tracking with off-target signaling bias is still the recurring failure mode — lotiglipron's discontinuation is the cautionary tale here. No convergent scaffold yet: four programs, four distinct chemotypes, still bespoke SAR rather than a template anyone can reuse. Orforglipron's approval is proof-of-concept, not a formula. Expect the same peptide-to-oral-small-molecule chase to hit GIP and glucagon receptor programs next.